Annals of hematology

asia-pacific journal of clinical oncology

[1] A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.

[2] reduction in incidence of early fatal complications of high-dose chemotherapy with autologous hematopoietic stem cell transplantation in hodgkin lymphoma patients

[3] hodgkin lymphoma mimicking osteomyelitis

[4] current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma

[5] pediatric lymphomas in brazil

[6] solitary renal pelvic lesion as the primary manifestation of hodgkin lymphoma: a case report

[7] histopathological evaluation of lymph node biopsies: a hospital based study

[8] Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.

[9] Pachymeningeal Involvement with Blindness as the Presenting Manifestation of Non-Hodgkin Lymphoma

[10] Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

[11] Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.

[12] Clinicopathological Characterization of Children With B-Cell Non-Hodgkin Lymphoma Over 10 Years at a Tertiary Center in Cape Town, South Africa.

[13] Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.

[14] A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.

[15] Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.

[16] NLP Hodgkin lymphoma: can we get away with less?

[17] Evaluation of the circulating and splenic lymphocyte subpopulations in patients with non-hodgkin lymphomas and Hodgkin's disease using monoclonal antibodies

[18] Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)

[19] quality of life among non-hodgkin lymphoma survivors

[20] concurrent presentation of hodgkin lymphoma and multiple myeloma

[21] nodular lymphocyte-predominant hodgkin lymphoma in progressive transformation of germinal centers

[22] novel brentuximab vedotin combination therapies show promising activity in highly refractory cd30+ non-hodgkin lymphoma: a case series and review of the literature

[23] primary non-hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of hpv and ebv status

[24] pediatric mature b-cell non hodgkin lymphoma treatment with lmb-96 protocol. the children cancer hospital egypt experience

[25] reduction in incidence of early fatal complications of high-dose chemotherapy with autologous hematopoietic stem cell transplantation in hodgkin lymphoma patients

[26] microarray expression technology in clinical research of non-hodgkin lymphoma

[27] non-hodgkin lymphoma as a cause of acute intestinal obstruction/perforation in patients with adenocarcinoma of the sigmoidcolon: a case report

[28] hodgkin lymphoma mimicking osteomyelitis

[29] current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma

[30] acquired natural killer cell dysfunction in the tumor microenvironment of classic hodgkin lymphoma

[31] testicular involvement in relapsed hodgkin lymphoma

[32] refractory classical hodgkin lymphoma presenting with atypical cutaneous involvement and diagnosis of zz phenotype alpha-1 antitrypsin deficiency

[33] infused autograft lymphocyte to monocyte ratio predicts survival in classical hodgkin lymphoma

[34] tumor necrosis factor-308 polymorphism with the risk and prognosis of non-hodgkin lymphomas: a meta-analysis study

[35] treatment of advanced hodgkin lymphomas in adolescents and young adults: efficacy and toxicity issues

[36] rit with y90-ibritumomab tiuxetan in follicular non-hodgkin lymphoma: evaluation of recent outcomes in a single institution

[37] increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-hodgkin lymphoma in a north american population

[38] solitary renal pelvic lesion as the primary manifestation of hodgkin lymphoma: a case report

[39] primary extranodal, extralymphatic hodgkin lymphoma of the mandible

[40] synchronous bilateral breast carcinoma and axillary non-hodgkin lymphoma: a case report and review of the literature

[41] Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.

[42] Comparison between skeletal muscle and adipose tissue measurements with high-dose CT and low-dose attenuation correction CT of 18 F-FDG PET/CT in elderly Hodgkin lymphoma patients: a two-centre validation

[43] Erratum to: “Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection Among Men Who Have Sex With Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study” and “CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies”

[44] Erratum to: “Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection Among Men Who Have Sex With Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study” and “CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies”

[45] Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection

[46] A rare localization of a common disease: Primary uterine Non-Hodgkin lymphoma mimicking leiomyosarcoma.

[47] [Clinical Efficiency of Rituximab Combined with Autologous Hematopoietic Blood Stem Cell Transplantation for Treatment of CD20 B non.Hodgkin Lymphoma].

[48] Different expression of MIB1 in primary site of non-Hodgkin lymphoma and its bone marrow deposits, a pilot study